There are 717 resources available
Key messages and wrap up
Presenter: Jonathan Ledermann
Session: ESMO Colloquium supported by GSK: Breakthroughs in molecular profiling and systemic therapies of endometrial and ovarian cancer
Resources:
Slides
Webcast
Live Q&A and live discussion
Presenter: Dawakar Davar
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Webcast
Innate agonists in cancer immunotherapy: Part 1
Presenter: Jason Luke
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Slides
Webcast
Innate agonists in cancer immunotherapy: Part 2
Presenter: Dawakar Davar
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Slides
Webcast
Oncolytic viruses in cancer immunotherapy
Presenter: Dmitriy Zamarin
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Slides
Webcast
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session